Paper Details

  1. Home
  2. Paper Details

Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.

Author: , ColletteLaurence, DeboisMuriel, FossåSophie D, HoekstraWytze, KarthausPeter P M, KurthKarl Heinz, SchröderFritz H

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study suggests an advantage for early endocrine treatment for prostate cancer, but it is underpowered to show equivalence or superiority. The potential survival advantage on early treatment must be balanced against potential advantages in quality of life on delayed treatment.
Paper Details　
Original Abstract of the Article :
PURPOSE: The timing of endocrine treatment for prostate cancer remains controversial. The issue is addressed in protocol 30846 of the European Organisation for Research and Treatment of Cancer for patients with lymph node positive cancer without local treatment of the primary tumor. MATERIALS AND M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/01.ju.0000135742.13171.d2

データ提供：米国国立医学図書館（NLM）

Timing is Key: Exploring the Optimal Endocrine Treatment for Prostate Cancer

This phase III study addresses the ongoing debate surrounding the optimal timing of endocrine treatment for prostate cancer, focusing on patients with lymph node-positive disease without local treatment of the primary tumor. The researchers compared the outcomes of immediate versus delayed endocrine treatment, finding no significant difference in overall survival. However, their findings suggest a potential advantage for early treatment, highlighting the importance of careful consideration of individual patient factors.

Prostate Cancer: A Complex Desert to Navigate

This research illuminates the complexities of treating prostate cancer, where the timing of endocrine therapy plays a crucial role. It's like navigating a vast and intricate desert, where different pathways lead to different outcomes. The authors emphasize the importance of individualizing treatment decisions to achieve the best possible results.

The Importance of Personalized Care

This study underscores the need for personalized care in treating prostate cancer. It's like recognizing that every traveler in the desert has unique needs and requirements for survival. The authors highlight the importance of considering individual patient factors and weighing the potential benefits and risks of different treatment approaches.

Dr.Camel's Conclusion

This study offers valuable insights into the timing of endocrine treatment for prostate cancer, highlighting the importance of individualized care and careful consideration of patient factors. It's like navigating a vast and complex desert, where the right path for one traveler may not be suitable for another. The authors emphasize the need for ongoing research and collaboration to optimize treatment strategies for this challenging disease.

Date :
  1. Date Completed 2004-09-03
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15310999

DOI: Digital Object Identifier

10.1097/01.ju.0000135742.13171.d2

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.